dc.contributor.author | Martinez-Lopez, J | |
dc.contributor.author | Sanchez-Vega, B | |
dc.contributor.author | Barrio, S | |
dc.contributor.author | Cuenca, I | |
dc.contributor.author | Ruiz-Heredia, Y | |
dc.contributor.author | Alonso, R | |
dc.contributor.author | Rapado, I | |
dc.contributor.author | Marin, C | |
dc.contributor.author | Cedena, M-T | |
dc.contributor.author | Paiva, B | |
dc.contributor.author | Puig, N | |
dc.contributor.author | Mateos, M-V | |
dc.contributor.author | Ayala, R | |
dc.contributor.author | Hernandez, M-T | |
dc.contributor.author | Jimenez, C | |
dc.contributor.author | Rosinol, L | |
dc.contributor.author | Martinez, R | |
dc.contributor.author | Teruel, Ana Isabel | |
dc.contributor.author | Gutierrez, N | |
dc.contributor.author | Martin-Ramos, Maria-Luisa | |
dc.contributor.author | Oriol, A | |
dc.contributor.author | Bargay Lleonart, Joan | |
dc.contributor.author | Blade, J | |
dc.contributor.author | San-Miguel, J | |
dc.contributor.author | Garcia-Sanz, R | |
dc.contributor.author | Lahuerta, J-J | |
dc.date.accessioned | 2024-07-11T09:07:19Z | |
dc.date.available | 2024-07-11T09:07:19Z | |
dc.date.issued | 2017-06 | |
dc.identifier.citation | Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17. | en |
dc.identifier.issn | 0887-6924 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/10944 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20381 | |
dc.description.sponsorship | This study was supported by the Cooperative Research Thematic Network grant RD12/0036/0061 of the Red de Cancer (Cancer Network of Excellence RTICC); the Subdireccion General de Investigacion Sanitaria (Instituto de Salud Carlos III, Spain) grants PI15/02062 and PI15/01484; the CRIS against Cancer foundation grant 2014/0120; Joan Rodes grant (JR 14/00016); and Undergraduate Fellowship IFI14/00008. | es_ES |
dc.language.iso | eng | en |
dc.publisher | Nature Publishing Group | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Monitoring, Physiologic | * |
dc.subject.mesh | Multiple Myeloma | * |
dc.subject.mesh | Neoplasm, Residual | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | High-Throughput Nucleotide Sequencing | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Survival Analysis | * |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | * |
dc.title | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma | en |
dc.type | letter to the editor | en |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.identifier.pubmedID | 28210002 | es_ES |
dc.format.volume | 31 | es_ES |
dc.format.number | 6 | es_ES |
dc.format.page | 1446-1449 | es_ES |
dc.identifier.doi | 10.1038/leu.2017.58 | |
dc.identifier.e-issn | 1476-5551 | es_ES |
dc.relation.publisherversion | https://dx.doi.org/10.1038/leu.2017.58 | en |
dc.identifier.journal | Leukemia | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Humanos | * |
dc.subject.decs | Protocolos de Quimioterapia Combinada Antineoplásica | * |
dc.subject.decs | Análisis de Supervivencia | * |
dc.subject.decs | Anciano | * |
dc.subject.decs | Monitoreo Fisiológico | * |
dc.subject.decs | Mieloma Múltiple | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Secuenciación de Nucleótidos de Alto Rendimiento | * |
dc.subject.decs | Neoplasia Residual | * |
dc.subject.decs | Masculino | * |
dc.identifier.scopus | 2-s2.0-85014659967 | |
dc.identifier.wos | 402832700025 | |
dc.identifier.pui | L614736600 | |